PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
a 6% decline for the pediatric indication, primarily reflecting the unfavorable impact of COVID-19 and lower year-over-year birth rates (8) ; Ibrance in the U.S., Ibrance (palbociclib). RE47,739 for Ibrance by more than four years until March 2027. Hospital products, which grew 10% operationally to $2.3 Product Developments.
40 
Let's personalize your content